Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Open-Label Study of HTX-011 Via Individualized Dosing Administration for Postoperative Analgesia Following Unilateral Simple Bunionectomy

Trial Profile

A Phase 2 Open-Label Study of HTX-011 Via Individualized Dosing Administration for Postoperative Analgesia Following Unilateral Simple Bunionectomy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Jan 2019

At a glance

  • Drugs Bupivacaine/meloxicam (Primary) ; Aprepitant
  • Indications Postoperative pain
  • Focus Pharmacokinetics
  • Sponsors Heron Therapeutics
  • Most Recent Events

    • 02 Jan 2019 Aprepitant drug has been added in the study and two treatment arms has been added. also patient number also increased.
    • 02 Jan 2019 Planned number of patients changed from 30 to 60.
    • 02 Jan 2019 Planned End Date changed from 2 Jan 2019 to 7 Feb 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top